Shopping Cart
Remove All
Your shopping cart is currently empty
Semaglutide-13C6,15N TFA
Copy Product Info
😃Good
Catalog No. TMID-0971
Semaglutide-13C6,15N TFA, marked with 13C and 15N isotopes, is a form of Semaglutide TFA. This compound is a long-acting, selective, competitive, orally active GLP-1R agonist capable of crossing the blood-brain barrier. Upon GLP-1R activation, it stimulates insulin secretion, inhibits gastric emptying and appetite, and enhances autophagy while reducing oxidative stress and apoptosis (apoptosis). Additionally, it modulates mitochondrial function and lipid metabolism, such as reducing hepatic de novo lipogenesis. Semaglutide TFA exhibits activities including blood glucose reduction, weight loss, neuroprotection (such as improving motor function in Parkinson’s disease models and reducing α-synuclein aggregation), and amelioration of hepatic steatosis. It is useful for research into type 2 diabetes, obesity, Parkinson’s disease, metabolic-associated steatotic liver disease (MASLD), other neurodegenerative conditions, liver diseases, and cancer.
Semaglutide-13C6,15N TFA
Semaglutide-13C6,15N TFA
Copy Product Info😃Good
Catalog No. TMID-0971
Semaglutide-13C6,15N TFA, marked with 13C and 15N isotopes, is a form of Semaglutide TFA. This compound is a long-acting, selective, competitive, orally active GLP-1R agonist capable of crossing the blood-brain barrier. Upon GLP-1R activation, it stimulates insulin secretion, inhibits gastric emptying and appetite, and enhances autophagy while reducing oxidative stress and apoptosis (apoptosis). Additionally, it modulates mitochondrial function and lipid metabolism, such as reducing hepatic de novo lipogenesis. Semaglutide TFA exhibits activities including blood glucose reduction, weight loss, neuroprotection (such as improving motor function in Parkinson’s disease models and reducing α-synuclein aggregation), and amelioration of hepatic steatosis. It is useful for research into type 2 diabetes, obesity, Parkinson’s disease, metabolic-associated steatotic liver disease (MASLD), other neurodegenerative conditions, liver diseases, and cancer.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | Inquiry | Inquiry | |
| 50 mg | Inquiry | Inquiry | Inquiry |
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Resource Download
Product Introduction
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | Semaglutide-13C6,15N TFA, marked with 13C and 15N isotopes, is a form of Semaglutide TFA. This compound is a long-acting, selective, competitive, orally active GLP-1R agonist capable of crossing the blood-brain barrier. Upon GLP-1R activation, it stimulates insulin secretion, inhibits gastric emptying and appetite, and enhances autophagy while reducing oxidative stress and apoptosis (apoptosis). Additionally, it modulates mitochondrial function and lipid metabolism, such as reducing hepatic de novo lipogenesis. Semaglutide TFA exhibits activities including blood glucose reduction, weight loss, neuroprotection (such as improving motor function in Parkinson’s disease models and reducing α-synuclein aggregation), and amelioration of hepatic steatosis. It is useful for research into type 2 diabetes, obesity, Parkinson’s disease, metabolic-associated steatotic liver disease (MASLD), other neurodegenerative conditions, liver diseases, and cancer. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, and a total of 10 animals are to be administered, using a formulation of 
10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.Stock Solution Preparation:
Dissolve 2 mg of the compound in 100 μL DMSO to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
Preparation of the In Vivo Formulation:
1) Add 100 μL of the DMSO stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O and mix thoroughly until a homogeneous solution is obtained.
This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy Semaglutide-13C6,15N TFA | purchase Semaglutide-13C6,15N TFA | Semaglutide-13C6,15N TFA cost | order Semaglutide-13C6,15N TFA
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.